At a hospital in Coventry, surgeons are no longer required to close a patient and wait weeks to learn whether they have truly finished their work. A hybrid scanning machine called the Aura-10 now sits in the operating theater itself, returning high-resolution images of removed tumors within ten minutes — collapsing a four-to-five-week pathology delay into a single unbroken surgical moment. In a field where uncertainty has long meant unnecessary suffering, this technology asks a quiet but profound question: what becomes of follow-up treatment when the surgeon already knows the answer before lea
West Midlands hospital deploys world-first cancer scanner in operating theater
Patients currently undergoing unnecessary radiotherapy due to incomplete cancer removal could benefit from more precise surgical outcomes.
Certain the cancer is gone before closing the incision
Mark
Why does ten minutes matter so much? Surgeons already know they're removing a tumor.
Mimi
Because they don't know if they got all of it. A surgeon can see the obvious mass, but cancer cells spread. The pathology lab tells you what you actually removed—but that takes weeks. By then the patient is home, thinking they're done. Aura-10 tells you while they're still asleep on the table.
Mark
So the surgeon could go back in and remove more?
Mimi
Exactly. Or know with certainty they're finished. Right now, one in four prostate cancer patients finds out weeks later that they need radiotherapy anyway. That's a second round of treatment, more side effects, more time off work. Aura-10 could eliminate that for most people.
Mark
What's the catch? Why isn't every hospital doing this?
Mimi
Cost is one thing—a quarter million pounds. But also, it's new. They're still running the trial. Hospitals move slowly, especially the NHS. You have to prove it works, prove it's reliable, prove it saves money in the long run. That's what they're doing now.
Mark
And it's working?
Mimi
So far, yes. The machine's readings match what the labs produce. If that holds through the full trial, this becomes a no-brainer. Faster answers, fewer repeat treatments, less strain on pathology departments that are already drowning.
Mark
How many patients could this affect?
Mimi
Thousands, potentially. Every prostate cancer surgery, every head and neck cancer surgery. If it works as well as early results suggest, you're talking about reshaping cancer care across the country.
Il Polso
- Roughly one in four prostate cancer operations in the UK leaves cancer behind, sending patients back for radiotherapy they might never have needed if the surgeon had known sooner.
- The traditional pathology pipeline — weeks of waiting, a lab queue, a delayed verdict — has long forced a painful gap between surgery and certainty.
- The Aura-10, a mobile CT-PET hybrid small enough to wheel into an operating room, collapses that gap to ten minutes, letting surgeons confirm clean margins before closing the incision.
- University Hospital Coventry and Warwickshire is now the first institution in the world to deploy this technology in the operating theater for prostate cancer, with results so far matching conventional lab findings.
- The trial is only halfway complete, but the clinical and financial stakes are already clear — fewer patients facing unnecessary radiation, and real relief for an NHS histopathology service under chronic strain.
At a hospital in Coventry, surgeons are no longer required to close a patient and wait weeks to learn whether they have truly finished their work. A hybrid scanning machine called the Aura-10 now sits in the operating theater itself, returning high-resolution images of removed tumors within ten minutes — collapsing a four-to-five-week pathology delay into a single unbroken surgical moment. In a field where uncertainty has long meant unnecessary suffering, this technology asks a quiet but profound question: what becomes of follow-up treatment when the surgeon already knows the answer before leaving the room?
University Hospital Coventry and Warwickshire has become the first hospital in the world to bring a scanner called the Aura-10 directly into the operating theater — a move that could fundamentally change how surgeons understand whether they have done their job completely.
The Aura-10 is a mobile hybrid unit combining CT and PET scanning technology. Once a tumor is removed, it is placed inside the machine and a high-resolution image is returned within ten minutes. The contrast with the traditional pathway is stark: under current practice, excised tissue travels to a pathology lab and waits in a queue for four to five weeks. If residual cancer is found, the patient — already home — must return for chemotherapy or radiotherapy. With Aura-10, that verdict arrives before the incision is closed.
The hospital is the first in Britain to use the technology for prostate cancer. Donald MacDonald, a urology consultant at the trust, describes it as an "absolute game changer," pointing to national figures showing that around one in four prostate cancer operations leaves some disease behind. That statistic represents thousands of patients each year facing additional treatment that more precise intraoperative knowledge might have prevented.
At £250,000, the equipment represents a significant outlay, but the financial argument runs deeper. The NHS is chronically short of histopathologists — the specialists who analyze tissue samples. A machine that performs this function in real time reduces pressure on those labs and, over time, cuts the cost of follow-up treatment for patients who would otherwise have needed it.
Oludolapo Adesanya, the trial's principal investigator, is careful to note that the evaluation is still ongoing — roughly at its midpoint. But early results are aligning with traditional pathology findings, and the ambition is clear: if the trial holds, Aura-10 could move from a single theater in Coventry to standard use across the NHS, reshaping cancer surgery for thousands of patients each year.
University Hospital Coventry and Warwickshire has become the first hospital in the world to expand the use of a scanner called Aura-10 into the operating theater itself—a shift that could reshape how surgeons know, in real time, whether they've removed all the cancer from a patient's body.
The machine is a hybrid: it combines a CT scanner and a PET scanner into a single mobile unit small enough to wheel into an operating room. Once a tumor has been removed, the surgeon can place it directly into the Aura-10 and have a high-resolution image back within ten minutes. That speed matters enormously. Under the traditional pathway, a removed tumor goes to a pathology lab, where it sits in a queue for four to five weeks while technicians analyze it. By then, the patient has already left the hospital. If the lab finds that cancer remains, the patient must return for chemotherapy or radiotherapy—additional treatment that might have been avoided if the surgeon had known the truth on the operating table.
The hospital is the first in Britain to use Aura-10 for prostate cancer specifically, though the technology has applications across head and neck cancers as well. Donald MacDonald, a urology consultant at the trust, has been operating with the machine and calls it an "absolute game changer for prostate cancer surgery." The numbers bear him out: nationally, about one in four prostate cancer operations leaves some cancer behind. Those patients then face radiotherapy to mop up what the surgeon missed. With Aura-10, MacDonald said, he can be certain before closing the incision that the cancer is gone.
The equipment costs around £250,000—a significant investment for any hospital. But the financial case extends beyond the price tag. The NHS faces chronic shortages in histopathology, the specialty that analyzes tissue samples. A machine that can do this work in the operating room, instantly, reduces the burden on those labs and means fewer patients will need follow-up radiation. Over time, that compounds into real savings.
Oludolapo Adesanya, the clinical lead for nuclear medicine and the trial's principal investigator, emphasized that this is still an experimental phase—the team is roughly halfway through their evaluation. But the results so far are matching what the traditional pathology labs produce. "In future," Adesanya said, "this could be used in a lot more areas of cancer care." The implication is clear: if the trial continues to hold, Aura-10 could move from a single operating theater in Coventry to become standard equipment across the NHS, changing the calculus of cancer surgery for thousands of patients each year.
Citazioni salienti
An absolute game changer for prostate cancer surgery— Donald MacDonald, urology consultant at UHCW
Results appear to be as good as the pathology labs and in future could be used in many more areas of cancer care— Oludolapo Adesanya, clinical lead for nuclear medicine
Vuoi la storia completa?
Leggi l'originale su Birmingham Live ↗
Health & Medicine